Delving into the Latest Updates on Bimekizumab with Synapse

Overview

Basic Info

Drug Type

Bispecific antibody

Synonyms

Anti-IL-17-mAb-UCB, Anti-IL-17-monoclonal-antibody-UCB, Anti-interleukin-17-monoclonal-antibody-UCB

+ [17]

Target

IL-17A x IL-17F

Action

inhibitors

Mechanism

IL-17A inhibitors(Interleukin 17A inhibitors), IL-17F inhibitors(Interleukin-17F inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Hidradenitis SuppurativaAnkylosing SpondylitisAxial Spondyloarthritis+ [10]

Inactive Indication

Chronic large plaque psoriasisColitis, UlcerativeInfluenza, Human+ [1]

Originator Organization

UCB SA

Active Organization

UCB SAUCB Biopharma SRLUCB Pharma SA

+ [7]

Inactive Organization

UCB Celltech

License Organization

BioRay Biopharmaceutical Co., Ltd.

UCB Trading (Shanghai) Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

European Union (20 Aug 2021),

Arthritis, PsoriaticPlaque psoriasis

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 9975662H

Source: *****

Sequence Code 13372170L

Source: *****

This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.

Start Date01 Sep 2026

Sponsor / Collaborator

Spyre Therapeutics, Inc.

ChiCTR2600129598

/ Not yet recruitingNot ApplicableIIT

Efficacy and Safety of Bimekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: A Single-Center Prospective Observational Study

Start Date01 Sep 2026

Sponsor / Collaborator-

NCT07352566

/ Not yet recruitingPhase 4IIT

Utilization of a Cutaneous Therapy In Situ Microdevice

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.
The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Start Date01 Aug 2026

Sponsor / Collaborator

The University of California, San Francisco

100 Clinical Results associated with Bimekizumab

Login to view more data

100 Translational Medicine associated with Bimekizumab

Login to view more data

100 Patents (Medical) associated with Bimekizumab

Login to view more data

447

Literatures (Medical) associated with Bimekizumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry

Article

Author: Kojanová, Martina ; Třešňák Hercogová, Jana ; Gkalpakiotis, Spyridon ; Nečas, Miroslav ; Jandová, Marie ; Vantuchová, Yveta ; Cetkovská, Petra ; Tichý, Martin ; Machovcová, Alena ; Rob, Filip

INTRODUCTION:

Switching biologics for psoriasis is common; however, data on switching to alternative treatments after failure of IL-23 inhibitors are limited.

METHODS:

A retrospective analysis was conducted to extract efficacy and drug survival data from the BIOREP registry from January 2015 to June 2025. The analysis included all patients with psoriasis who were switched from an IL-23 inhibitor to an IL-17 inhibitor during this period and had at least one follow-up visit recorded.

RESULTS:

A total of 102 patients were switched from an IL-23 inhibitor to an IL-17 inhibitor, with 92 (90.2%) of these switches occurring due to insufficient efficacy. In these 92 patients, PASI-75 was achieved in 82.6% after 3 months and in 73.5% after 12 months. Absolute PASI ≤ 1 was achieved by 66.3% of patients after 3 months and 52.9% after 12 months. Patients treated with bimekizumab had the highest probability of meeting both efficacy parameters, particularly an absolute PASI ≤ 1 after 3 months. The overall survival probability was 79.5% after 12 months and 68.1% after 24 months.

CONCLUSION:

For patients with an inadequate response to IL-23 inhibitors, switching to IL-17 inhibitors offers adequate efficacy in reaching current therapeutic goals during the first year of treatment.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years

Article

Author: Cross, Nancy ; Yamaguchi, Yukie ; Elewski, Boni ; Wixted, Krista ; Pinter, Andreas ; Szilagyi, Balint ; Merola, Joseph F. ; Gooderham, Melinda ; Kavanagh, Sarah ; Gisondi, Paolo

TRIAL REGISTRATION:

BE SURE (NCT03412747), BE VIVID (NCT03370133), BE RADIANT (NCT03536884), BE READY (NCT03410992), BE BRIGHT (NCT03598790).

01 Aug 2026·JOURNAL OF AUTOIMMUNITY

Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition

Article

Author: Voiculescu, Vlad ; Zabotti, Alen ; Macleod, Tom ; Trunfio, Francesca ; McGonagle, Dennis ; Altaie, Ala ; Tonutti, Antonio ; Shams, Kave ; Quartuccio, Luca ; Marzo-Ortega, Helena ; Selmi, Carlo ; Vandevelde, Claire ; Abacar, Kerem ; Meridor, Katya

BACKGROUND:

Interleukin (IL)-17 inhibitors are effective in treating psoriatic disease, but paradoxical inflammatory reactions can occasionally occur. Palmoplantar pustular psoriasis (PPP) onset or flares have been rarely reported with anti-IL-17A but not dual IL-17A/F inhibition (bimekizumab).

METHODS:

Retrospective study: patients developing PPP while on anti-IL-17 were retrieved from hospital databases.

RESULTS:

Ten new PPP cases occurred during treatment with anti-IL-17: median age 46 years (range 33-59), females 40%. Six patients were obese, five smokers. Different IL-17 inhibitors were implicated, including secukinumab (n = 4), ixekizumab (n = 4), and for the first reported time bimekizumab (n = 2). PPP occurred after a median of 3 months (range 1-60) from anti-IL-17 initiation, earlier in those who did not respond in the primary disease domain (2 months, range 1-3) compared to responders (median 10 months, 1-60). Management of PPP included anti-IL-17 retention with topical agents, ciclosporin or colchicine, switching within class, or swapping to other mechanisms of action (IL-23, TNF, and JAK inhibition). Clinical benefit was reported with all approaches on available follow-up.

CONCLUSIONS:

PPP is rare during IL-17 inhibition but can occur under dual IL-17A/F inhibition. The underlying immunological mechanisms may involve neutrophil inflammation that independent from type-17 immune response.

216

News (Medical) associated with Bimekizumab

12 Aug 2026

·www.biospace.com

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

SPY772 program aims to deliver best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation Phase 2 SKYLIGHT trial designed to provide clinical proof-of-concept for TL1A and IL-17A/F inhibition in Hidradenitis Suppurativa; site activation has begun with topline Week 16 HiSCR75 data planned for late 2027 or early 2028 WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the launch of SPY772, a new combination program comprising SPY072, a long-acting anti-TL1A antibody, and SPY007, a novel long-acting anti-IL-17A/F antibody in preclinical development. To test the hypothesis of the SPY772 program, the company also announced the initiation of SKYLIGHT, a randomized Phase 2 proof-of-concept trial evaluating dual inhibition of TL1A and IL-17A/F in Hidradenitis Suppurativa (HS). “Combination therapy has demonstrated the ability to meaningfully improve efficacy without apparent safety downsides in multiple autoimmune conditions. We believe our differentiated strategy of developing long-acting antibody coformulations against validated targets appears increasingly likely to deliver indication-leading product pro ” said Sheldon Sloan, M.D., Chief Medical Officer. “Expanding our portfolio to include long-acting IL-17A/F broadens the potential for our pipeline to improve outcomes across some of the largest gastrointestinal, dermatologic, and rheumatic diseases with substantial remaining unmet medical need.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); "HS is a chronic, painful disease that can profoundly affect patients' quality of life, and many patients do not achieve adequate disease control with available therapies. We believe targeting complementary inflammatory pathways has the potential to raise the efficacy ceiling in HS," said Josh Friedman, M.D., Ph.D., SVP of Clinical Development and SKYLIGHT study lead. "SKYLIGHT will evaluate whether adding SPY072 (anti-TL1A) to bimekizumab (anti-IL-17A/F) can improve outcomes beyond bimekizumab alone. Positive SKYLIGHT results would support advancement of our long-acting SPY772 combination (SPY072 and SPY007) in HS. We are also excited to potentially explore other indications with this combination pending our SKYWAY trial results.” SKYLIGHT is a randomized, placebo-controlled Phase 2 proof-of-concept study expected to enroll approximately 150 adults with moderate-to-severe HS. Participants will receive background bimekizumab therapy and either SPY072 or placebo. The primary endpoint is the proportion of patients achieving a HiSCR75 response at Week 16. Topline results are expected in late 2027 or early 2028. About Spyre Therapeutics Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs. For more information, visit Spyre's website at . Forward-Looking Statements Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding: Spyre’s ability to achieve the expected benefits or opportunities with respect to its product candidates and combinations thereof, including its ability to develop next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients and its ability to develop long-acting antibody coformulations against validated targets to deliver indication-leading product pro the potential for SPY772 to provide best-in-indication efficacy and convenience in Hidradenitis Suppurativa through dual inhibition of TL1A and IL-17A/F in a long-acting coformulation; the potential of raising the efficacy ceiling in HS by targeting complementary inflammatory pathways; and Spyre’s ongoing and future pre-clinical and clinical development activities, including Spyre’s plans for and timing of data readouts and clinical enrollment for the SKYLIGHT trial, preclinical development of the SPY007 program and the potential expansion of the SPY772 program to indications outside of HS. The words "opportunity," "potential," "milestones," "pipeline," "strategy," "anticipate," "believe," "could," "estimate," "expect," "may," "might," "plan," "possible," "predict," "should," "will," "would," "can, " "likely," "aim," and similar expressions (including the negatives of these terms) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs and involve a number of risks and uncertainties, many of which are beyond Spyre’s control, and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the topline or interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and any other filings that Spyre has made or may make with the SEC from time to time. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. For Investors: Eric McIntyre, Spyre Therapeutics SVP of Finance and Investor Relations Eric.mcintyre@spyre.com For Media: Josie Butler, 1AB josie@1abmedia.com

Phase 2Immunotherapy

02 Jul 2026

·www.fiercebiotech.com

Fosun pays $32M to join Lilly and Novartis in fiercely competitive psoriasis market

A Fosun Pharma subsidiary has paid Junshi Biosciences 215 million yuan ($32 million) for Chinese rights to a near-approval autoimmune disease drug. The deal grants the wholly owned subsidiary, Fosun Wanbang Pharmaceutical, rights to roconkibart in Greater China. Roconkibart is an anti-IL-17A antibody that Junshi has developed in moderate-to-severe plaque psoriasis. A Chinese phase 3 trial of the candidate, which is also called JS005, hit its primary endpoint, leading Junshi to apply for approval in its home market last year. Fosun Wanbang has stepped in to develop, register and commercialize the asset in Greater China under an exclusive license. The deal also gives the company a co-exclusive license to manufacture the product in Greater China. The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing to pay double-digit tiered royalties on net sales for the rights. The milestones are split (PDF) between 180 million yuan ($27 million) tied to product development and 945 million yuan ($139 million) based on sales. Fosun Wanbang will enter a competitive market. Novartis won approval for its IL-17A inhibitor Cosentyx in plaque psoriasis in China in 2019. Since then, the list of IL-17A drugs approved for psoriasis in China has grown to include Eli Lilly’s Taltz , Suzhou Suncadia Biopharmaceutical’s vunakizumab , Genrix Biopharmaceutical’s xeligekimab , UCB’s Bimzelx and Akeso’s gumokimab . CSPC Pharmaceutical recently won (PDF) approval for a Cosentyx biosimilar. Roconkibart is unlikely to be the last IL-17A inhibitor that Chinese authorities approve in the indication. Livzon Pharmaceutical’s lecankitug, which like Bimzelx targets IL-17A and IL-17F, beat (PDF) Cosentyx in a head-to-head psoriasis trial and is under review in China. Fosun Wanbang will enter the fight for market share, equipped with phase 3 data showing that 91% of people on roconkibart achieved at least a 90% improvement in symptoms after 16 weeks. By Week 52, 65% of people had a 100% improvement. The data are in line with results for Akeso’s recently approved gumokimab, which achieved a 100% improvement in 68.9% of patients at Week 52.

24 Jun 2026

·allsci.com

MoonLake boosts public offering to USD 200m for sonelokimab

Switzerland-based MoonLake Immunotherapeutics (Nasdaq: MLTX) announced the pricing of an upsized underwritten public offering of Class A ordinary shares and pre-funded warrants, raising approximately USD 200 million in gross proceeds to fund pre-commercialization and commercialization activities for sonelokimab ahead of a planned Biologics License Application submission in hidradenitis suppurativa. The offering was upsized from an initial target of USD 150 million announced two days earlier, a 33% increase that indicates strong institutional demand ahead of what would be MoonLake’s first regulatory filing. The offering comprises 9,000,000 Class A ordinary shares priced at USD 20.00 per share, with pre-funded warrants available to certain investors in lieu of shares at USD 19.9999 per warrant, exercisable immediately. Underwriters were granted a 30-day option to purchase up to an additional 1,500,000 shares at the public offering price. MoonLake stated proceeds will be used alongside existing cash to fund sonelokimab research, development, pre-commercialization, and commercialization activities, if approved, and for general corporate purposes. Leerink Partners, Guggenheim Securities, Cantor, and LifeSci Capital are acting as joint bookrunning managers, with H.C. Wainwright and Clear Street as lead managers. Company overview and pipeline MoonLake is a clinical-stage biopharmaceutical company founded in 2021 and built around a single licensed asset, sonelokimab (SLK), acquired from Merck KGaA. Sonelokimab is an approximately 40 kDa humanized Nanobody that simultaneously inhibits IL-17A and IL-17F by blocking the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation, with a third domain binding human serum albumin to extend half-life and facilitate tissue penetration. The lead program is in hidradenitis suppurativa (HS), where the Phase III VELA-1 and VELA-2 trials enrolled 838 patients. Week 52 data reported in June 2026 showed 67.2% HiSCR75 and 33.1% HiSCR100 response rates across both studies. The VELA-TEEN trial in adolescents aged 12–17 reported 68% HiSCR75 at Week 24. Following a positive final pre-BLA meeting with the FDA in April 2026, MoonLake plans to submit the HS BLA by end of September 2026. A US commercial launch, absent Priority Review, is targeted for Q3/Q4 2027. The capital raise is timed to build the commercial infrastructure required ahead of that launch. As of Q1 2026, MoonLake held USD 357.9 million in cash and short-term marketable securities, with a runway projected to end-2027; the USD 200 million raise materially extends that runway into the commercialization phase. In psoriatic arthritis, the Phase III IZAR-1 and IZAR-2 trials are enrolling approximately 1,500 adults, with primary endpoint readouts expected in mid and late 2026, respectively. Sonelokimab also holds FDA Fast Track designation in palmoplantar pustulosis, supported by positive Phase II LEDA data, with a Phase III program planned. The Phase II S-OLARIS trial in axial spondyloarthritis reported 81% ASAS40 response at Week 12 alongside PET imaging evidence of reduced osteoblast activity, though no Phase III program in that indication has been announced. Sonelokimab competes directly with UCB’s bimekizumab (Bimzelx), currently the leading approved dual IL-17A/F inhibitor in HS, as well as established biologics including adalimumab and secukinumab. MoonLake’s Week 52 HiSCR75 data numerically exceed bimekizumab’s reported rates at comparable timepoints, though cross-trial comparisons are constrained by differences in trial design and patient populations. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 3Clinical ResultPhase 2Fast TrackDrug Approval

100 Deals associated with Bimekizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11550	Bimekizumab	-	DB12917

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hidradenitis Suppurativa	European Union	UCB Pharma SA	30 Apr 2024
Hidradenitis Suppurativa	Iceland	UCB Pharma SA	30 Apr 2024
Hidradenitis Suppurativa	Liechtenstein	UCB Pharma SA	30 Apr 2024
Hidradenitis Suppurativa	Norway	UCB Pharma SA	30 Apr 2024
Ankylosing Spondylitis	European Union	UCB Pharma SA	15 Jun 2023
Ankylosing Spondylitis	Iceland	UCB Pharma SA	15 Jun 2023
Ankylosing Spondylitis	Liechtenstein	UCB Pharma SA	15 Jun 2023
Ankylosing Spondylitis	Norway	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	European Union	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	Iceland	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	Liechtenstein	UCB Pharma SA	15 Jun 2023
Axial Spondyloarthritis	Norway	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	European Union	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	Iceland	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	Liechtenstein	UCB Pharma SA	15 Jun 2023
Non-radiographic axial spondyloarthritis	Norway	UCB Pharma SA	15 Jun 2023
Erythrodermic psoriasis	Japan	UCB Japan Co., Ltd.	20 Jan 2022
Psoriasis vulgaris	Japan	UCB Japan Co., Ltd.	20 Jan 2022
Pustular psoriasis	Japan	UCB Japan Co., Ltd.	20 Jan 2022
Arthritis, Psoriatic	European Union	UCB Pharma SA	20 Aug 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pustulosis of Palms and Soles	Phase 3	United States	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	China	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	China	UCB Pharma SA	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	Canada	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	Czechia	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	Denmark	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	France	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	Germany	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	Hungary	UCB Biopharma SRL	14 Nov 2025
Pustulosis of Palms and Soles	Phase 3	Italy	UCB Biopharma SRL	14 Nov 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03928743 \| NCT03928704 (BE MOBILE 1, Pubmed \| J Rheumatol)	Phase 3	Arthritis, Psoriatic \| Axial Spondyloarthritis	1,698	Bimekizumab	bziuyfomyj(axwshgzzty) = cbatkyqtoc txxvuhixax (egneguvvht ) View more	Positive	01 Jul 2026
				Placebo	bziuyfomyj(axwshgzzty) = fwqbcorwat txxvuhixax (egneguvvht ) View more
NCT04436640 \| NCT03928743 \| NCT03928704 (BE MOBILE 1, Pubmed \| J Rheumatol)	Phase 3	Axial Spondyloarthritis	574	Bimekizumab 160 mg (Axial Spondyloarthritis)	vtyootcoob(cqoaepmehs) = rjlmaaaohz ridsjgrkan (ezdrloioqu ) View more	Positive	15 Jun 2026
NCT03928704 (BE MOBILE 1, EULAR2026)	Phase 3	Non-radiographic axial spondyloarthritis	254	Bimekizumab	idffwecupt(swmngmxzie) = gwnqruujuj wymeqlpijz (apxnxtautu ) View more	Positive	11 Jun 2026
NCT06624228 (BE BOLD, EULAR2026)	Phase 3	Arthritis, Psoriatic	553	Bimekizumab	tjyoyhhfnm(cwhavsxbok) = tpwyiewjdq ivvnpmwyos (bykbvserhx ) View more	Superior	11 Jun 2026
				Risankizumab	tjyoyhhfnm(cwhavsxbok) = vsuepgspel ivvnpmwyos (bykbvserhx ) View more
EULAR2026	Not Applicable	Arthritis, Psoriatic	787	Bimekizumab	vooiyesrhm(nqexmpiobj) = jfkxoezjxr dtdtrcmibx (dypkrpdvnk ) View more	Positive	11 Jun 2026
				Bimekizumab (0 prior b/tsDMARDs)	evalgfrwcp(shbdqqorjk) = jbzbghootd bjvzpdyely (anjujwrajr ) View more
EULAR2026	Not Applicable	Psoriasis \| Arthritis, Psoriatic \| Axial Spondyloarthritis	42	Bimekizumab (Psoriatic Arthritis, Psoriasis, or Axial Spondyloarthritis)	zdonmikijo(pchqcbagwv) = nffcwermct lxwcjvhnzt (zlwqkmxdlk ) View more	Positive	11 Jun 2026
SPEAK (EULAR2026)	Not Applicable	Axial Spondyloarthritis	197	Bimekizumab	hzchpprkmc(qwppegfeml) = yiebveidnb rtxxafyfws (uesfiqxlsj ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Arthritis, Psoriatic	773	Bimekizumab (Psoriatic Arthritis)	ervuvbjzfh(rvlijkrkjf) = btgcfesgde vgxwaemrar (tefeuiyaov ) View more	Positive	11 Jun 2026
EULAR2026	Not Applicable	Arthritis, Psoriatic \| Axial Spondyloarthritis	152	Bimekizumab (PsA)	gryzxyoimo(csrmsxbbqg) = svidncbciz prkycafcuq (uverisaaju ) View more	Positive	11 Jun 2026
				Bimekizumab (peripheral PsA)	dqofucwupn(censrwxoke) = asokfyxxdv camebjxeaw (ccbdgcbnxc )
NCT03895203 (BE OPTIMAL, EULAR2026)	Phase 3	Arthritis, Psoriatic	1,112	Placebo	lzzcgyijyd(imtqrmwuzb) = mugcwvscll qzgodzpysm (mxbkumnpsb ) View more	Positive	11 Jun 2026
				Bimekizumab	lzzcgyijyd(imtqrmwuzb) = wsrtuxmgqr qzgodzpysm (mxbkumnpsb ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data